303 related articles for article (PubMed ID: 15879784)
1. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen.
Karakiewicz PI; Benayoun S; Kattan MW; Perrotte P; Valiquette L; Scardino PT; Cagiannos I; Heinzer H; Tanguay S; Aprikian AG; Huland H; Graefen M
J Urol; 2005 Jun; 173(6):1930-4. PubMed ID: 15879784
[TBL] [Abstract][Full Text] [Related]
2. [Prospective validation of a nomogram predictive of a positive initial prostate biopsy].
Ramírez-Backhaus M; Bahilo P; Arlandis S; Santamaría Navarro C; Pontones Moreno JL; Jiménez-Cruz F
Actas Urol Esp; 2010 Jan; 34(1):35-42. PubMed ID: 20223131
[TBL] [Abstract][Full Text] [Related]
3. PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy.
Elshafei A; Chevli KK; Moussa AS; Kara O; Chueh SC; Walter P; Hatem A; Gao T; Jones JS; Duff M
Prostate; 2015 Dec; 75(16):1951-7. PubMed ID: 26384170
[TBL] [Abstract][Full Text] [Related]
4. Development and external validation of an extended 10-core biopsy nomogram.
Chun FK; Briganti A; Graefen M; Montorsi F; Porter C; Scattoni V; Gallina A; Walz J; Haese A; Steuber T; Erbersdobler A; Schlomm T; Ahyai SA; Currlin E; Valiquette L; Heinzer H; Rigatti P; Huland H; Karakiewicz PI
Eur Urol; 2007 Aug; 52(2):436-44. PubMed ID: 17010505
[TBL] [Abstract][Full Text] [Related]
5. Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL.
Kawamura K; Suzuki H; Kamiya N; Imamoto T; Yano M; Miura J; Shimbo M; Suzuki N; Nakatsu H; Ichikawa T
Int J Urol; 2008 Jul; 15(7):598-603. PubMed ID: 18462353
[TBL] [Abstract][Full Text] [Related]
6. Head-to-head comparison of the Montreal nomogram with the detection of primary malignant circulating prostate cells to predict prostate cancer at initial biopsy in Chilean men with suspicion of prostate cancer.
Murray NP; Reyes E; Fuentealba C; Orellana N; Jacob O; Badilla S
Urol Oncol; 2015 May; 33(5):203.e19-25. PubMed ID: 25746939
[TBL] [Abstract][Full Text] [Related]
7. Development, validation and comparison of two nomograms predicting prostate cancer at initial 12-core biopsy.
Nowroozi MR; Amini S; Kasaeian A; Zavarehei MJ; Eshraghian MR; Ayati M
Asia Pac J Clin Oncol; 2016 Jun; 12(2):e289-97. PubMed ID: 24684767
[TBL] [Abstract][Full Text] [Related]
8. Development of improved nomogram for prediction of outcome of initial prostate biopsy using readily available clinical information.
Zaytoun OM; Kattan MW; Moussa AS; Li J; Yu C; Jones JS
Urology; 2011 Aug; 78(2):392-8. PubMed ID: 21705045
[TBL] [Abstract][Full Text] [Related]
9. History of malignancy is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram.
Kawakami S; Koga F; Fujii Y; Saito K; Yamamoto S; Tatokoro M; Yonese J; Kageyama Y; Fukui I; Kihara K
Int J Urol; 2008 Dec; 15(12):1055-60. PubMed ID: 19054174
[TBL] [Abstract][Full Text] [Related]
10. A nomogram for prediction of prostate cancer on multi-core biopsy using age, serum prostate-specific antigen, prostate volume and digital rectal examination in Singapore.
Lee A; Lim J; Gao X; Liu L; Chia SJ
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e348-e355. PubMed ID: 27641069
[TBL] [Abstract][Full Text] [Related]
11. A direct comparison of the diagnostic accuracy of three prostate cancer nomograms designed to predict the likelihood of a positive initial transrectal biopsy.
Ouzaid I; Yates DR; Hupertan V; Mozer P; Chartier-Kastler E; Haertig A; Bitker MO; Rouprêt M
Prostate; 2012 Aug; 72(11):1200-6. PubMed ID: 22213470
[TBL] [Abstract][Full Text] [Related]
12. The outcomes of transrectal ultrasound guided biopsy of the prostate in a New Zealand population.
Lienert AR; Davidson PJ; Wells JE
N Z Med J; 2009 Jan; 122(1288):39-49. PubMed ID: 19182841
[TBL] [Abstract][Full Text] [Related]
13. Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL.
Eastham JA; May R; Robertson JL; Sartor O; Kattan MW
Urology; 1999 Oct; 54(4):709-13. PubMed ID: 10510933
[TBL] [Abstract][Full Text] [Related]
14. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL.
Garzotto M; Hudson RG; Peters L; Hsieh YC; Barrera E; Mori M; Beer TM; Klein T
Cancer; 2003 Oct; 98(7):1417-22. PubMed ID: 14508828
[TBL] [Abstract][Full Text] [Related]
15. The nomogram conundrum: a demonstration of why a prostate cancer risk model in Turkish men underestimates prostate cancer risk in the USA.
Kara O; Elshafei A; Nyame YA; Akdogan B; Malkoc E; Gao T; Altan M; Citamak B; Mammadov E; Dursun F; Greene DJ; Senkul T; Ates F; Ozen H; Stephen Jones J
Int Urol Nephrol; 2016 Oct; 48(10):1623-9. PubMed ID: 27236298
[TBL] [Abstract][Full Text] [Related]
16. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH
Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592
[TBL] [Abstract][Full Text] [Related]
17. External validation of a PCA-3-based nomogram for predicting prostate cancer and high-grade cancer on initial prostate biopsy.
Greene DJ; Elshafei A; Nyame YA; Kara O; Malkoc E; Gao T; Jones JS
Prostate; 2016 Aug; 76(11):1019-23. PubMed ID: 27197726
[TBL] [Abstract][Full Text] [Related]
18. Development and external validation of an extended repeat biopsy nomogram.
Chun FK; Briganti A; Graefen M; Porter C; Montorsi F; Haese A; Scattoni V; Borden L; Steuber T; Salonia A; Schlomm T; Latchemsetty K; Walz J; Kim J; Eichelberg C; Currlin E; Ahyai SA; Erbersdobler A; Valiquette L; Heinzer H; Rigatti P; Huland H; Karakiewicz PI
J Urol; 2007 Feb; 177(2):510-5. PubMed ID: 17222622
[TBL] [Abstract][Full Text] [Related]
19. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
[TBL] [Abstract][Full Text] [Related]
20. Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy.
Kawakami S; Numao N; Okubo Y; Koga F; Yamamoto S; Saito K; Fujii Y; Yonese J; Masuda H; Kihara K; Fukui I
Eur Urol; 2008 Sep; 54(3):601-11. PubMed ID: 18207312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
